Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AuspiCiOus: Retifanlimab + CapOx in dMMR Esophagogastric Cancer
NCT05177133Phase 2Recruiting
- Sponsor
- University of Amsterdam
- Start
- Nov 2021
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by University of Amsterdam. Started Nov 2021; status: recruiting.
02
Drugs
retifanlimab
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT05177133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177133.